The Federal Circuit has scheduled the oral argument of Amgen’s appeal from the district court’s judgment of non-infringement of Apotex’s proposed biosimilars of Neupogen® (filgrastim) and Neulasta® (pegfilgrastim) for 2:00pm on October 3, 2017 at the Benjamin N. Cardozo School of Law Burns Moot Courtroom. As previously reported, the Federal Circuit will also hear oral argument that same day in the Janssen v. Celltrion appeal related to Remicade® (infliximab). Stay tuned to the Big Molecule Watch blog for developments.
